Literature DB >> 23942323

Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria.

I Koti1, K Weller, M Makris, E Tiligada, T Psaltopoulou, C Papageorgiou, I Baiardini, D Panagiotakos, F Braido, M Maurer.   

Abstract

BACKGROUND: The impact of chronic spontaneous urticaria (CSU) on health-related quality of life (HRQoL) is widely held to be mainly influenced by disease activity and comorbidities.
OBJECTIVE: To assess the correlation between disease activity and HRQoL impairment by using validated disease-specific instruments.
METHODS: The Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) was translated into Greek and subsequently applied to 110 CSU patients along with the Dermatology Life Quality Index and the Urticaria Activity Score. After the validity and reliability of the Greek CU-Q2oL had been determined, we assessed the relation between disease activity and HRQoL impairment by computing correlations as well as by performing multiple regression analysis.
RESULTS: Exploratory factor analysis revealed a six-scale structure of the Greek CU-Q2oL that explained 67.9% of its total variance. The internal consistency was satisfactory with Cronbach's α >0.7. Disease activity was the only predictor of quality of life impairment, but it only moderately correlated with the CU-Q2oL total score (r = 0.40, p < 0.0001).
CONCLUSION: Our results suggest that there are additional factors to disease activity that are responsible for the pronounced reduction of HRQoL in CSU, and this supports the recommendation to assess and monitor both disease activity and quality of life in CSU patients.

Entities:  

Mesh:

Year:  2013        PMID: 23942323     DOI: 10.1159/000351711

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  10 in total

Review 1.  Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020.

Authors:  Marcus Maurer; Kilian Eyerich; Stefanie Eyerich; Marta Ferrer; Jan Gutermuth; Karin Hartmann; Thilo Jakob; Alexander Kapp; Pavel Kolkhir; Désirée Larenas-Linnemann; Hae-Sim Park; Gunnar Pejler; Mario Sánchez-Borges; Knut Schäkel; Dagmar Simon; Hans-Uwe Simon; Karsten Weller; Torsten Zuberbier; Martin Metz
Journal:  Int Arch Allergy Immunol       Date:  2020-03-30       Impact factor: 2.749

2.  Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.

Authors:  William R Lumry; Karsten Weller; Markus Magerl; Aleena Banerji; Hilary J Longhurst; Marc A Riedl; Hannah B Lewis; Peng Lu; Giovanna Devercelli; Gagan Jain; Marcus Maurer
Journal:  Allergy       Date:  2020-12-24       Impact factor: 13.146

3.  Vitamin d supplements improve urticaria symptoms and quality of life in chronic spontaneous urticaria patients: a prospective case-control study.

Authors:  Tadech Boonpiyathad; Panitan Pradubpongsa; Atik Sangasapaviriya
Journal:  Dermatoendocrinol       Date:  2014-07-16

4.  Impact of chronic urticaria on the quality of life of patients followed up at a university hospital.

Authors:  Gabriela Andrade Coelho Dias; Gisele Viana Pires; Solange Oliveira Rodrigues do Valle; Sérgio Duarte Dortas; Soloni Levy; Alfeu Tavares França; Ilaria Baiardini; Walter Giorgio Canonica
Journal:  An Bras Dermatol       Date:  2016 Nov-Dec       Impact factor: 1.896

5.  Sense of coherence as a protective factor in chronic urticaria.

Authors:  Alicja Ograczyk; Joanna Miniszewska; Anna Pietrzak; Anna Zalewska-Janowska
Journal:  Postepy Dermatol Alergol       Date:  2017-04-13       Impact factor: 1.837

6.  Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America.

Authors:  Ivan Cherrez-Ojeda; Marcus Maurer; Jonathan A Bernstein; Emanuel Vanegas; Miguel Felix; German D Ramon; Luis Felipe Ensina; José Ignacio Larco Sousa; Edgar Emilio Matos Benavides; R Cardona Villa; P Latour Staffeld; Blanca María Morfin-Maciel; Jose Mori; Paul Wilches C; Valeria L Mata; Annia Cherrez
Journal:  World Allergy Organ J       Date:  2019-02-23       Impact factor: 4.084

7.  Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling.

Authors:  Donald E Stull; Doreen McBride; Katherine Houghton; Andrew Y Finlay; Ari Gnanasakthy; Maria-Magdalena Balp
Journal:  Adv Ther       Date:  2016-01-30       Impact factor: 3.845

8.  Patient-reported outcomes in urticarial vasculitis treated with omalizumab: case report.

Authors:  Ivan Cherrez-Ojeda; Emanuel Vanegas; Miguel Felix; Valeria L Mata; Annia Cherrez
Journal:  BMC Dermatol       Date:  2018-10-25

9.  Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study).

Authors:  Ignacio Jauregui; Ana Gimenez-Arnau; Joan Bartra; Moises Labrador-Horrillo; Javier Ortiz de Frutos; Juan Francisco Silvestre; Joaquin Sastre; Manuel Velasco; Marta Ferrer; Cristina Ballesteros; Antonio Valero
Journal:  Health Qual Life Outcomes       Date:  2019-01-31       Impact factor: 3.186

10.  Psychometric properties of the portuguese version of the chronic urticaria quality of life questionnaire (CU-Q2oL).

Authors:  Pedro Lopes Ferreira; Margarida Gonçalo; José Alberto Ferreira; Ana Célia Costa; Ana Todo-Bom; Cristina Lopes Abreu; Ana Rita Travassos; Pedro Andrade; Ilaria Baiardini; Giorgio Walter Canonica
Journal:  Health Qual Life Outcomes       Date:  2019-12-30       Impact factor: 3.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.